Tracking shifts in competitiveness: from scientific capability to medicine availability

Clicks: 7
ID: 337594
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #164 of 168 articles by views in Health Affairs Scholar

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 168 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Current United States pricing reforms have renewed debate about whether policies intended to improve medicine affordability may also influence pharmaceutical investment and development. We examine indicators of scientific capability, commercial conditions, regulatory performance, pharmaceutical research and development investment, and medicine availability across China, Europe, Japan, and the United States, using public and industry-derived sources. Pharmaceutical research investment grew rapidly in China and the United States but remained broadly stable in Japan. Between 2018 and 2023, commercial clinical-trial starts in China increased from 727 to 1,412, a cumulative increase of 94.2%. Trial starts increased from 472 to 546 in Japan but declined from 1,850 to 1,719 in the United States and from 1,253 to 920 in the European Economic Area. Among 460 medicines launched globally during 2012–2021, reported availability was 85% in the United States, 51% in Japan, 39% on average across European countries, and 24% in China. These patterns indicate shifts in relative pharmaceutical competitiveness but do not identify their causes or estimate the effects of individual policies. Evaluations of United States pricing reforms should consider government and patient savings alongside potential changes in investment, clinical development, launch decisions, and medicine availability.
Reference Key
openalex_W7224083387 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tosin Adeyemo, Tim Wilsdon
Are you one of these authors? Claim your profile
Journal Health Affairs Scholar
Year 2026
DOI
10.1093/haschl/qxag303
URL
https://academic.oup.com/healthaffairsscholar/advance-article-pdf/doi/10.1093/haschl/qxag303/72548096/qxag303.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.